Skip to main content
. 2020 Mar 26;8(6):1042–1055. doi: 10.12998/wjcc.v8.i6.1042

Table 5.

Independent predictors of 28-d outcomes in hepatitis B virus-related acute-on-chronic liver failure patients combined with bacterial infections

Variable Survivors (n = 58) Nonsurvivors (n = 99) Univariate Cox regression
Multivariate Cox regression
HR (95%CI) P value HR (95%CI) P value
Age (yr) 45.5 ± 9.7 49.3 ± 10.7 1.023 (1.005-1.042) 0.013
Male (%) 53 (91.4) 82 (82.8) 0.693 (0.410-1.170) 0.170
Cirrhosis (%) 50 (86.2) 85 (85.9) 0.956 (0.543-1.684) 0.877
SIRS (%) 17 (29.3) 58 (58.6) 2.214 (1.480-3.310) < 0.001
Temperature (°C) 37.1 (36.6, 38.0) 37.1 (36.6, 38.0) 1.055 (0.861-1.293) 0.604
MAP (mmHg) 86.9 ± 11.4 88.9 ± 15.5 1.003 (0.987-1.019) 0.696
Invasive catheterization (%) 6 (10.3) 26 (26.3) 2.026 (1.290-3.181) 0.002 2.173 (1.320-3.579) 0.002
Grade of ACLF
ACLF-1 (%) 44 (75.9) 35 (35.4) Reference < 0.001
ACLF-2 (%) 12 (20.7) 29 (29.3) 1.977 (1.205-3.243) 0.007
ACLF-3 (%) 2 (3.4) 35 (35.4) 4.648 (2.862-7.548) < 0.001
HBV DNA (log10 IU/ml) 3.6 (2.3, 5.5) 4.7 (2.8, 6.6) 1.083 (0.997-1.177) 0.060
WBC (×109/L) 7.5 (5.6, 11.3) 10.4 (6.9, 15.0) 1.054 (1.022-1.088) 0.001
NEUT (×109/L) 5.4 (3.4, 8.6) 8.5 (5.1, 12.7) 1.058 (1.023-1.094) 0.001
HGB (g/L) 105.0 ± 21.6 109.3 ± 26.3 1.003 (0.994-1.011) 0.516
PLT (×109/L) 64.0 (46.8, 88.5) 63.0 (40.0, 98.0) 1.000 (0.995-1.005) 0.984
ALB (g/L) 28.0 (25.0, 31.0) 28.0 (23.0, 31.0) 0.984 (0.945-1.024) 0.435
TBIL (μmol/L) 353.6 ± 130.9 356.4 ± 163.7 1.000 (0.999-1.001) 0.836
DBIL (μmol/L) 257.4 ± 88.3 236.8 ± 113.7 0.998 (0.996-1.000) 0.091
ALT (IU/L) 76.5 (35.3, 127.8) 103.0 (49.0, 352.0) 1.001 (1.000-1.001) 0.003
AST (IU/L) 118.0 (71.0, 165.0) 136.0 (85.0, 367.0) 1.001 (1.000-1.001) < 0.001
ALP (IU/L) 158.5 (125.8, 211.3) 137.0 (99.0, 179.0) 1.000 (0.998-1.001) 0.721
GGT (IU/L) 49.0 (35.8, 78.8) 56.0 (33.0, 78.0) 0.999 (0.995-1.004) 0.821
Cr (μmol/L) 98.5 (79.5, 126.3) 122.0 (87.0, 196.0) 1.002 (1.001-1.003) 0.001
Na (mmol/L) 133.0 (130.0, 136.0) 132.0 (128.0, 136.0) 0.996 (0.962-1.031) 0.830
INR 1.9 (1.7, 2.3) 2.6 (2.1, 3.3) 1.762 (1.487-2.089) < 0.001
PTA (%) 33.2 ± 11.1 23.3 ± 9.9 0.937 (0.917-0.957) < 0.001 0.967 (0.941-0.993) 0.015
CRP (mg/L) 20.5 (13.2, 43.4) 16.2 (8.9, 39.6) 0.998 (0.991-1.005) 0.530
PCT (ng/mL) 1.2 (0.8, 1.8) 1.2 (0.6, 2.9) 1.017 (1.002-1.033) 0.025
Ascites (%) 57 (98.3) 96 (97.0) 0.578 (0.183-1.828) 0.351
AKI (%) 24 (41.4) 61 (61.6) 2.777 (1.734-4.449) < 0.001 2.187 (1.259-3.799) 0.005
HE (%) 23 (39.7) 76 (76.8) 1.635 (1.089-2.454) 0.018
AVB (%) 8 (13.8) 26 (26.3) 1.476 (0.942-2.312) 0.089
Pneumonia (%) 20 (34.5) 59 (59.6) 1.831 (1.222-2.744) 0.003
SBP (%) 34 (58.6) 33 (33.3) 0.553 (0.364-0.842) 0.006
BSI (%) 6 (10.3) 20 (20.2) 1.661 (1.016-2.715) 0.043 2.339 (1.384-3.952) 0.002
Other BIs (%) 4 (6.9) 16 (16.2) 1.488 (0.870-2.544) 0.146
Multiple sites of BIs (%) 6 (10.3) 24 (24.2) 1.797 (1.132-2.852) 0.013
MDROs (%) 4 (6.9) 11 (11.1) 1.401 (0.728-2.696) 0.313
CA BIs (%) 4 (6.9) 13 (13.1) 1.537 (0.857-2.757) 0.149
HCA BIs (%) 24 (41.4) 47 (47.5) 1.046 (0.705-1.553) 0.821
Nosocomial BIs (%) 30 (51.7) 39 (39.4) 0.804 (0.537-1.204) 0.290
COSSH-ACLF Scores 6.1 (5.8, 6.7) 7.4 (6.6, 8.7) 1.704 (1.498, 1.937) < 0.001 1.371 (1.127-1.666) 0.002

SIRS: Systemic inflammation response syndrome; MAP: Mean arterial pressure; ACLF: Acute-on-chronic liver failure; HBV: Hepatitis B virus; WBC: White blood cells; NEUT: Neutrophil count; HGB: Hemoglobin; PLT: Platelet; ALB: Albumin; TBIL: Total bilirubin; DBIL: Direct bilirubin; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; ALP: Alkaline phosphatase; GGT: Gamma-glutamyl transpeptidase; Cr: Creatinine; Na: Sodium; INR: International normalized ratio; PTA: Prothrombin activity; CRP: C-reactive protein; PCT: Procalcitonin; AKI: Acute kidney injury; HE: Hepatic encephalopathy; AVB: Acute variceal bleed; SBP: Spontaneous bacterial peritonitis; BSI: Bloodstream infection; BIs: Bacterial infections; MDROs: Multidrug-resistant organisms; CA: Community-acquired; HCA: Healthcare-associated; COSSH: Chinese Group on the Study of Severe Hepatitis B.